The U.S. Wanted Switzerland’s Drug Prices. Switzerland Is Starting to Lose Drug Launches.

Seven of 22 innovative medicines were not submitted for Swiss reimbursement over U.S. MFN concerns. The deeper issue: what happens when a national price stops being national.